Overview

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
Phase:
Phase 3
Details
Lead Sponsor:
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Collaborator:
LENZ Therapeutics, Inc
Treatments:
Aceclidine
Brimonidine Tartrate
Ophthalmic Solutions
Pharmaceutical Solutions